Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs.
Femasys has an expansive, internally-created intellectual property portfolio with over 130 patents issued globally for our products and product candidates.
De Novo Clinical Study
- IDE approval received from FDA in April 2021
- Commenced De Novo clinical trial third quarter of 2021 with planned completion in 2022
Infertility Products and Product Candidates
- Expand commercialization
PMA Clinical Studies
STAGE II VALIDATION
Contraception Product Candidate
- Commence PMA clinical trial after combined IDE submission approval in 2022
CE = European Commission
IDE = Investigational Device Exemption
FDA = Food and Drug Administration
PMA = Premarket approval
FemaSeed is a novel solution in development for insemination that can be performed as a first-line therapeutic option. It would be the first and only directed approach designed to be more affordable than assisted reproduction, such as in vitro fertilization (IVF).
Femvue® | FemCath™
FemBloc is in development as the first and only in-office approach to permanent birth control without the need for anesthesia or special equipment, which would make this nonsurgical option easy to incorporate into existing practices worldwide. With a potential to be less than half the total cost of a surgical tubal ligation, FemBloc enriches the physician’s practice. FemBloc also features the first and only ultrasound approach to confirm success 90 days after the procedure.
FemCerv is the first and only approach for comprehensive tissue sampling for the diagnosis of cervical cancer. We intend to market this diagnostic option alongside our other female-specific medical products to physicians’ offices.